MilliporeSigma, Oxford University Partner in Vaccine Mfg
MilliporeSigma has partnered with Oxford University’s Jenner Institute to develop more scalable vaccine-manufacturing processes. Separately, MilliporeSigma is developing plans for a vaccine-manufacturing facility in Africa.
The partners intend to improve the manufacturing process for adenovirus vaccines—vaccines based on adenovirus, a type of DNA virus, as a carrier—using MilliporeSigma products, systems and technologies on a real-world feed stream. By applying MilliporeSigma technology, the collaborators aim to develop a cost-effective and transferable manufacturing process that can be used to accelerate vaccine development and manufacturing. The collaboration is expected to result in a closed process that can be practiced in a cleanroom to minimize contamination, in line with the biological safety requirements for viral vectors.
Separately, MilliporeSigma is developing plans for a vaccine-manufacturing facility in Ghana. A recently signed memorandum of understanding between MilliporeSigma and Ridge Management Solutions provides the opportunity for Ghana to become the first country in Sub-Saharan Africa to have a dedicated human vaccine-manufacturing factory, according to MilliporeSigma.